Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Heart Failure Added to Clinically Significant ADR List for Xalkori
July 8, 2015
- MHLW Calls for Revision of Package Insert for Influenza HA Vaccine, Others
July 8, 2015
- Drug Pricing Tomorrow: Full Interview with MHLW Economic Affairs Head Jo - Part 1
July 8, 2015
- Govt to Stockpile Pre-Pandemic Flu Vaccine Based on Indonesia Strain in FY2015
July 7, 2015
- Editor’s Pick: Five Healthcare News Headlines for June 22 - July 5
July 6, 2015
- MHLW Approves Gilead’s Harvoni, Other Products
July 6, 2015
- NCC Eyes Trial Enrollment of 150 Rare Cancer Patients under Registry Initiative
July 3, 2015
- Official Denies Report, Says Govt Won’t Ask Research-Driven Firms to Make Generics
July 3, 2015
- MHLW to Accept Applications for Sakigake Designation for Regenerative Medicine Products, Medical Devices from Sept. 14
July 3, 2015
- LDP, Komeito Lawmakers’ Group Formed to Fight Hepatitis
July 2, 2015
- Drug Pricing Tomorrow: Full Interview with Ex-Chuikyo Chairman Endo
July 2, 2015
- Govt OKs Economic Growth Strategy, Regulatory Reform Plan
July 1, 2015
- Japan Cabinet OKs Fiscal Policy Guidelines, Marking Dawn of “80% Generic” Era
July 1, 2015
- PMDA Unveils New International Strategy
June 30, 2015
- MHLW Global Strategy Aims at Regulatory Shortcut for Japan-OK’ed Drugs
June 29, 2015
- Drug Pricing Tomorrow: MHLW’s Jo Says Price-Maintenance Premium Crucial as Post-Launch Reward for Innovation
June 29, 2015
- MHLW Approves Additional Indications for Radicut and Other Products
June 29, 2015
- 8 Members Exit Pharmaceutical Affairs Council
June 26, 2015
- LDP OKs Economic, Fiscal Policy Guidelines, but Wording on Reference Pricing Could Change
June 26, 2015
- Problems at Kaketsuken Remained Undetected Despite 21 On-Site Inspections over 10-Year Period: PMDA
June 26, 2015
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…